PDF(Pubmed)
Abstract：
Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz-estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.
摘要：
感染艾滋病毒和乳腺癌的妇女比艾滋病毒阴性妇女的生存率低。Efavirenz-雌激素相互作用被记录;然而，生存的影响是未知的。比较了雌激素受体阳性乳腺癌患者服用依非韦仑（n=38）和非依非韦仑（n=51）的生存率。依非韦伦组和非依非韦伦组的5年总生存率为48.9%[95%置信区间(CI)33.0-72.2和51.1%(95%CI34.0-76.8)]，分别表明,依非韦伦不太可能导致感染HIV和雌激素受体阳性乳腺癌的女性生存率下降.
